Metiltioninio Cloruro Monico

Methylthioninium chloride, the active ingredient in Metiltioninio Cloruro Monico, is a thiazine dye presented as an injectable solution for intravenous use. It is employed to rapidly reverse methemoglobinemia and to act as an antidote in cyanide poisoning, providing critical support in emergency and intensive‑care settings.

GNH USA supplies Metiltioninio Cloruro Monico as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, adhering to stringent quality standards and reliable global logistics.

Methylthioninium chloride is used in conditions where rapid reduction of oxidized hemoglobin or detoxification of cyanide is required.

Methemoglobinemia: rapid conversion of methemoglobin back to functional hemoglobin, restoring oxygen delivery. Cyanide poisoning: facilitates conversion of cyanide to less toxic metabolites, supporting cellular respiration. Urinary tract infection: exhibits antimicrobial activity that can aid in adjunctive treatment of certain bacterial infections.

Methylthioninium chloride may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting: gastrointestinal discomfort following administration. - Headache or dizziness: transient neurological sensations. - Mild hypertension: temporary increase in blood pressure. - Blue‑green discoloration of urine: harmless coloration due to the dye.

Serious or Rare Side Effects: - Hemolysis in patients with G6PD deficiency: rapid destruction of red blood cells. - Severe hypertension or hypertensive crisis: marked elevation of blood pressure requiring intervention. - Serotonin syndrome: risk when combined with serotonergic agents, presenting with agitation, hyperreflexia, and fever.

Methylthioninium chloride requires careful consideration of patient-specific factors and handling conditions.

G6PD deficiency: avoid use due to risk of hemolysis. Pregnancy: limited data; use only if potential benefit outweighs risk. Concurrent serotonergic drugs: monitor for signs of serotonin syndrome. Renal impairment: assess renal function and monitor for accumulation. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methylthioninium chloride can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs): increased risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): heightened potential for serotonin toxicity.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: possible additive blood pressure effects. - Local anesthetics such as prilocaine: may exacerbate methemoglobinemia. - Other oxidizing agents: monitor methemoglobin levels closely.